• Molecular NameMirtazapine
  • SynonymMepirzepine; Mirtazapina [INN-Spanish]; mirtazapine; Mirtazapine [Usan:Ban:Inn]; Mirtazapinum [INN-Latin]; Mirtazepine
  • Weight265.36
  • Drugbank_IDDB00370
  • ACS_NO61337-67-5
  • Show 2D model
  • LogP (experiment)3.3
  • LogP (predicted, AB/LogP v2.0)3.02
  • pka7.1
  • LogD (pH=7, predicted)2.64
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)-2.52
  • LogSw (predicted, AB/LogsW2.0)0.28
  • Sw (mg/ml) (predicted, ACD/Labs)0.1
  • No.of HBond Donors0
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds0
  • TPSA19.37
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA psychoactive drug of the benzazepine and tetracyclic antidepressant (TeCA) chemical classes which is used primarily as an antidepressant. It is sometimes used for its anxiolytic, hypnotic, antiemetic, orexigenic, and antihistamine or antipruritic effects.
  • Absorption_value100.0
  • Absorption (description)Rapid and complete, but, due to first-pass metabolism, absolute bioavailability is 50%.
  • Caco_2N/A
  • Bioavailability50.0
  • Protein binding85.0
  • Volume of distribution (VD)4.5 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMirtazapine is extensively metabolized by demethylation and hydroxylation followed by glucuronide conjugation. Cytochrome P450 2D6 and cytochrome P450 1A2 are involved in formation of the 8-hydroxy metabolite of mirtazapine, and cytochrome P450 3A4 is responsible for the formation of the N-desmethyl and N-oxide metabolites. Several metabolites possess pharmacological activity, but plasma levels are very low.
  • Half life16.3 h
  • Excretion75% urine, 15% feces
  • Urinary ExcretionN/A
  • Clerance9.12 ml/min/kg
  • ToxicitySymptoms of overdose include disorientation, drowsiness, impaired memory, and tachycardia.
  • LD50 (rat)LD50=mg/kg
  • LD50 (mouse)N/A